Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHEAD 3-45: Lecanemab in Preclinical Alzheimer's Disease (A45 and A3 Trials)
2020-004244-28Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lecanemab in Alzheimer's disease (AD) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Primary endpoints (A45). Started Nov 2022; status: completed.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2020-004244-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004244-28.